ESHRE is the largest reproductive medicine conference in Europe, highlighting cutting-edge research in the fields of reproduction, embryology and andrology to scientists, clinicians, patient associations and the general public. A record breaking 12,179 participants from 130 countries attended this year’s meeting.
As a clinical reproductive scientist, this was an excellent opportunity for Aideen to network, share best practice and learn about new developments within reproductive biology and medicine. Aideen was particularly interested in new research showing a link between male reproductive health and overall health status, and has since been working on a comprehensive ‘male health profile’ for men presenting with subfertility.
Although the majority of Aideen’s day-to-day work focuses on managing the Andrology team, she also takes a keen interest in research and development in the area, in particular novel male fertility diagnostic techniques. The team’s main poster submitted to ESHRE 2018 focused on the validation of one such test – the MiOXSYS system – an electrochemical assay for the measurement of oxidation reduction potential in human semen.
Oxidative stress is a major contributing factor to male infertility but is not yet routinely assessed in conventional semen analysis. The MiOXSYS study, led by Consultant Clinical Lead Dr Sheryl Homa, sought to validate this assay – a test which is more efficient, less time-consuming and cheaper to run than any existing technique for measuring oxidative stress.
The study found that the MiOXSYS assay is robust, consistently meeting the requirements and specifications to reliably and accurately measure static oxidation reduction potential in human semen. This is an exciting development for the TDL team and for the field of andrology in general, with the new assay hopefully becoming a routine part of diagnostic testing and aiding more effective management of male infertility in the near future.